---
title: "ORBUSNEICH's research and production base in Hangzhou has topped out"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261536173.md"
description: "ORBUSNEICH's research and production base in Fuyang, Hangzhou, completed its structural topping on the 16th, becoming the largest integrated facility in the world. It is expected to be fully operational by 2027, with an annual production capacity increase of 2.4 million units, reaching approximately 4.5 million units. The base covers an area of 20,000 square meters, with an investment of about 430 million RMB, focusing on PCI and PTA interventional products, among others. Establishing the Hangzhou base will enhance production capacity, promote the application of new technologies, strengthen the stability of the global supply chain, and seize market growth opportunities"
datetime: "2025-10-17T01:35:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261536173.md)
  - [en](https://longbridge.com/en/news/261536173.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261536173.md)
---

# ORBUSNEICH's research and production base in Hangzhou has topped out

ORBUSNEICH (06929.HK) announced that its research and production base located in Fuyang, Hangzhou, completed structural topping yesterday (16th), becoming the company's largest integrated research and production facility globally. It is expected to obtain all relevant licenses by 2027 and commence full production, at which point ORBUSNEICH's total annual production capacity will increase by approximately 2.4 million products annually, based on the current capacity of about 2.1 million balloons and stents.

The Hangzhou base covers an area of approximately 20,000 square meters, with a building area of nearly 60,000 square meters, focusing on the research and production of PCI and PTA interventional products, as well as structural heart disease devices. The total investment in the project is approximately 430 million RMB, equipped with automated production lines to reduce labor costs.

The group expects that the establishment of the Hangzhou base will significantly enhance high-quality production capacity, accelerate the incubation and application of new technologies, strengthen the stability of the global supply chain and overall competitiveness, and help seize the opportunities presented by the continuous growth of the global PCI and PTA device market

### Related Stocks

- [06929.HK](https://longbridge.com/en/quote/06929.HK.md)

## Related News & Research

- [Comey eyes new 'anti-weaponization' fund: 'I'm guessing I'll be in line'](https://longbridge.com/en/news/286948735.md)
- [Scott Jennings voices concern over Trump's $1.7B DOJ fund](https://longbridge.com/en/news/286922300.md)
- [World is more vulnerable to pandemics despite Covid-19 lessons, warns WHO](https://longbridge.com/en/news/286895865.md)
- [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)
- [Trump Delivers Confused Rambling After Claiming ’Every Agency' Has 'Scum'](https://longbridge.com/en/news/287086760.md)